2040 EORTC item Q168: the psychometric performance of a single-item indicator of side-effect burden for people with cancer Tamara Jones 1 , Florian Zeman 2 , Michael Koller 2 , Andreia Moura 3 , Claire Piccinin 3 , Sandra Nolte 1 1 Person-Centred Research, Eastern Health Clinical School, Monash University, Melbourne, Australia, 2 Center for Clinical Studies, University Hospital Regensburg, Regensburg, Germany, 3 Quality of Life Department, European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium Journal of Patient-Reported Outcomes 2026 , 10(Suppl 1) :2040 Aims Following the release of the US Food and Drug Administration (FDA) Guidance on core patient-reported outcomes in cancer clinical trials, there has been growing interest in using single items to measure treatment tolerability from the patients perspective
Pharmaceutical semaglutide undergoes identity testing, potency assays, purity analysis (HPLC), residual solvent testing, endotoxin testing (LAL), sterility testing, particulate matter testing, and stability testing under controlled conditions
doi: 10.1002/advs.202412817 54 WangX.PanL.NiuD.ZhouJ.ShenM.ZengZ.et al
Polypodium Leucotomos (Golden Polypody) Herb Powder, Alpha Lipoic Acid, Milk Thistle (as Seed Extract Std to 80% Silymarin)
.png.jpg)
